← All trials
NCT04526990
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Sep 15, 2020
- Primary completion
- Dec 30, 2021
- Completion date
- Jan 30, 2022
- First posted
- Aug 26, 2020
- Last posted
- Dec 21, 2020
- Enrollment
- 40000
- Arms / groups
- 2 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Tianjin Cansino Biotechnology IncLead sponsor
- Government of ChinaOverall official - principal investigator
- Canadian Center for VaccinologyOverall official - principal investigator
- Beijing Institute of BiotechnologyCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.